M&A · Healthcare · Biological Products, (No Diagnostic Substances)
Sanofi to acquire Vigil Neuroscience, Inc.
Announced May 21, 2025 · Closed Aug 5, 2025
Deal value$470MEV $418M
Premium246.0%To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash$8.00 per share
Transaction
- Acquirer
- Sanofi (SNY)
- Target
- Vigil Neuroscience, Inc. (VIGL)
- Buyer type
- Strategic
- Offer price per share
- $8.00
- Enterprise value
- $418M
- Status
- Closed Aug 5, 2025
Deal protections
- Break fee (target pays)
- $22.2M · 4.7%
- Reverse fee (buyer pays)
- $31.1M · 6.6%
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- Centerview
- Centerview fee
- $14.3M
Sector context · Healthcare
- Comparable deals
- 92 in the prior 24 months
- Premium
- 246.0% vs. 67.0% sector median
- EV / Adj. EBITDA
- Sector median 14.5x
- Break fee
- 4.7% vs. 3.4% sector median
Timeline
- AnnouncedMay 21, 2025
- Proxy filedJun 16, 2025
- Definitive proxyJun 30, 2025
- Shareholder voteAug 4, 2025
- ClosedAug 5, 2025
Valuation · fairness opinions
Discounted cash flow$4.40$5.40
Analyst price targets$11.00$22.00
Premiums paid$4.45$7.45
Offer $8.00
Implied value per Vigil Neuroscience, Inc. share by analysis, from Centerview · DCF discount rate 15%–16.5%.